Part 3: Risk-based Quality Management Video (RBQM) Series
ICH Q9 (1) focuses on Quality Risk Management. Revisions may influence how we apply and perform risk management in clinical trials. In part three of our RBQM video series, Amy Kissam-Sands and Tim Audin, Senior Director, Global Biometrics Group Lead talk with Taren Grom, Editor, PharmaVOICE about the specific areas they expect ICH Q9 (1) to focus on.
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025